Summary The mechanism of action of the novel heterocycle 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), structurally related to temozolomide, was studied in the human ovarian tumour cell line OVCAR-3. Our results showed that, despite its marked structural similarities to temozolomide, PYRZ presents properties that are atypical of 1,2,3-triazene-containing alkylating agents. In a Maxam-Gilbert DNA sequencing assay, PYRZ showed background levels of DNA alkylation, in contrast to temozolomide which strongly alkylated DNA preferentially at guanine residues. At high concentrations, PYRZ inhibited the synthesis of DNA, RNA and protein 3 h after treatment, in contrast to temozolomide which, in previous work, was found to preferentially inhibit DNA synthesis in OVCAR-3 cells. In cells exposed to PYRZ, alkaline sucrose density-gradient centrifugation showed a dose-dependent increase in DNA fragmentation only 12 and 24 h after treatment. PYRZ induced increasing accumulation of cells in late S and G2+M 6-24 h after treatment. This also contrasts with previous work that showed delayed cell cycle arrest induced by temozolomide in OVCAR-3 cells and in the murine leukaemia Li 210 cells. Cell-killing kinetics by PYRZ showed a series of sigmoidal dose-response curves with 50-90% cell killing attained as early as 24 h after treatment in the 25-100 gM dose range. (IC50 clonogenic assay 18 FM). The results suggest that the mechanism of cell killing by PYRZ may be different from that of its parent drug temozolomide, and other alkyl-triazene-containing molecules of the same class.
Temozolomide (1) is a tetranitrogen heterocycle with significant clinical activity against malignant melanoma, high-grade glioma and mycosis fungoides (Foedstad et al, 1985; O'Reilly et al, 1993) . Recently , it has been shown in a pilot study to be extremely active in patients with primary brain tumours who relapsed following radiotherapy. Under physiological conditions, temozolomide generates a monomethyltriazene species that alkylates DNA (Baig et al, 1987) . There is accumulating evidence to show that only the alkylation of guanine at the 06 position is the critical event leading to cell death. Cells containing 06-alkylguanine transferase (AGT), an enzyme capable of repairing this lesion, are resistant to temozolomide (Catapano et al, 1987; Deans et al, 1992; Baer et al, 1993 ). This limit is also known for other alkylating agents such as alkylnitrosoureas and alkyltriazenes Hartley et al, 1986; Chen et al, 1993) . Recently, we have designed a novel class of heterocycles based on the structural modification of the 1,2,3,5-tetrazin-4-one backbone of temozolomide: the 1,2,3,5-tetrazepin-4-ones (Jean-Claude and Just, 1991; Jean-Claude, 1992; Jean-Claude et al, 1994 , 1996 . Taking the bridge nitrogen out of the aromatic system and keeping it electron poor by placing it in the 2-position of a pyridine ring gave the 6-7 fused heterocycle (2; PYRZ). The latter compound and other 1,2,3,5-tetrazepin-4-one ring-containing derivatives were found to show significant cytotoxicity in a panel of human tumour cell lines, including high AGT-expressing brain, breast and colon tumour cells (Jean-Claude et al, 1995) . Although the new compounds share structural similarities witti temozolomide, they exhibit markedly different chemical properties. As an example, X-ray crystallography shows that PYRZ adopts a nonplanar seven-membered ring boat shape (Figure 1 ), whereas temozolomide is almost perfectly planar (Clark et al, 1990; Lowe et al, 1992) . (The X-ray data supporting this conformation have been submitted to the journal as supplementary materials). Chemical differences between temozolomide and the tetrazepinones prompted us to investigate the mechanism of the in vitro action of the latter. This study describes the effects of tetrazepinone (2; PYRZ) on the human ovarian tumour cell line OVCAR-3. The effects are occasionally compared with that of temozolomide. PYRZ showed rapid cell-killing kinetics and an ability to induce detectable singlestrand breaks in OVCAR-3 cells only 12 and 24 h after treatment. PYRZ was capable of inducing significant cell cycle arrest in late S and G2+M as early as 6 h after treatment. This drug did not appear to be an inhibitor of DNA synthesis. The OVCAR-3 cells (Hamilton et al, 1983) obtained from the National Cancer Institute (NCI) were maintained as a monolayer culture at 37°C in a humidified atmosphere of 5% carbon dioxide/95% air in RPMI-1640 medium supplemented with fetal bovine serum (10%), L-glutamine (2 mM), penicillin (50 U ml-1) and streptomycin (50 mg ml-'). Cells were maintained in logarithmic growth by harvesting with a trypsin/EDTA solution containing 0.5 mg ml of trypsin and 0.2 mg ml-' of EDTA, and replating before cells reached confluency. Growth studies showed a doubling time of approximately 30 h. In all assays, the cells were plated for 24 h before drug administration.
Cytotoxicity and cell-killing kinetics
Cell monolayers were incubated with varying amounts of PYRZ for different time periods (continuous exposure) and cytotoxicity evaluated by the sulphorhodamine B assay (Skehan et al, 1991) . Briefly, at each appropriate time, the cells were fixed by the addition of 50 ,l of cold trichloroacetic acid (TCA) (50%) at 40C for British Journal of Cancer (1997) 
Flow cytometry
The effect of a 2-h exposure to PYRZ on the cycle of OVCAR-3 cells was evaluated after recovery times of 6, 12 and 24 h. The cells were harvested by trypsinization at the appropriate times. After fixation in ethanol (70%, v/v), the cells were stained with an aqueous propidium iodide (PI) solution (100 pl, 100 gg ml-') containing RNAase (100 gl, 50 gg ml-') for 30 min at room temperature in the dark. The fluorescence was detected in a spectral range between 580 and 750 nm. Each cytometric analysis was performed on a Becton Dickinson FACScan instrument on 1-3 x 105 cells. The percentage of cells in each cell cycle phase was estimated using LYSYS II software (Becton Dickinson).
Transport study Studies on kinetics of precursor transport were performed as described previously (Hayward et al, 1984) . The OVCAR-3 cells were seeded for 24 h in 24-well plates at a density of 6 x 105 cells per well. PYRZ was added to the medium at various concentrations. After a 2-h treatment the drug was removed by washing with phosphate-buffered saline (PBS) (2 x 2 ml) and fresh medium was added. The cells were allowed to recover for 3 h, after which fresh medium containing 0.3 ,uCi ml-' [14C]thymidine was added. Label uptake was allowed to proceed for various intervals at 0°C (2, 5, 10, 20 or 35 min). The medium was removed and the wells rapidly washed with cold PBS (2 x 2 ml). The cells were detached with 100 ,l of trypsin and dissolved in 3 ml of liquid scintillation fluid (Universol). The radioactivity was counted in a beta-scintillation counter.
Sequence specificity of guanine-N-7 alkylation Plasmid pRGM21, which was used to determine guanine specific N-7 alkylation, has been described in detail (Nobile et al, 1986 (Zsido et al, 1991) . Post-labelling (18-24 h) was performed before drug treatment. The drug was added for 2 h and the cells were allowed to grow in fresh medium for 24 h. They were then washed twice with PBS and dislodged by gentle scraping. To the 3H-labelled cells was added an aliquot of untreated 14C-labelled cells to serve as internal control during sedimentation analysis. The cells were then lysed in the dark at 0°C (lysis buffer: 0.55 N sodium hydroxide, 0.45 M sodium chloride, 10 mM Na2 EDTA, 0.015% sarcosyl) and layered on the top of 5-30% sucrose gradients containing 0.3 N sodium hydroxide, 0.7 M sodium chloride, and 10 mM Na2EDTA. Sedimentation was carried out at 4°C in a SW41 rotor of a centrifuge usually at 16 000 r.p.m. overnight. Gradients were fractioned by upward displacement with 1 ml of a dye dissolved in 40% sucrose and the samples collected with a BioRad fraction collector. The 0.3-ml fractions were analysed by single-phase liquid scintillation counting (dual-label settings).
RESULTS

Cytotoxicity
Survival curves for OVCAR-3 cells treated with PYRZ are shown in figure 2A and B. A clonogenic assay gave an IC50 of 18 gM. The cell-killing kinetics, as determined by the sulphorhodamine B assay, showed that the rate of cell kill was rapid and time dependent only beyond a critical dose (around 20 JUM). At high concentrations (50-100 gM), 90% kill was achieved within 24 h.
Macromolecule synthesis
The effect of PYRZ on precursor incorporation was evaluated and the results are shown in Figure 3 . Following a 2-h drug exposure and a 3-h recovery in drug-free media, a significant inhibition of DNA, RNA and protein synthesis was observed at high concentrations (50-100 JiM). At 24 h recovery in drug-free medium, the inhibition of the synthesis of all three macromolecules was released. A slight increase in uridine and thymidine incorporation was apparent. Leucine uptake remained unchanged. In order to determine whether the simultaneous inhibition of the synthesis of all three macromolecules was due to an alteration of precursor transports, the effect of PYRZ on the kinetics of label uptake was studied. As shown in Figure 4 , no significant effect was observed on the rate of incorporation of thymidine at 3 h after treatment even at 100 gM, a concentration that induced a 50% inhibition of macromolecule synthesis.
Flow cytometry
The effect of PYRZ on cell cycle was evaluated by flow cytometry (Figure 5) . A dose-dependent increase in cell accumulation in late S and G2+M was observed as early as 6 h after treatment. This effect was markedly enhanced at 12 and 24 h after treatment, with appearance at high concentrations of a sub-G, population of cellular debris at the left portion of the histograms. Two-dimensional forward light scatter DNA plots dia not show any size reduction for these populations, thus excluding the possibility that they might be apoptotic cells.
DNA damage PYRZ (1 mM) was allowed to react for 2 h with the HindIIIVSphI sequence of SV40 DNA and the damage was analysed using the Maxam-Gilbert sequencing technique. Temozolomide induced significant levels of guanine N-7 alkylation. In contrast, PYRZ induced background levels of DNA alkylation (lane A) (Figure 6 ).
DNA damage induced by PYRZ in OVCAR-3 cells was studied by alkaline sucrose-density gradient as described (Zsido et al, 1991) (Figure 7) . At 3 h post treatment, no DNA damage was observed over the whole dose range (data not shown). The DNA damage that appeared at 12 h at the high concentrations persisted at 24 h recovery and was accompanied by significant cell death.
DISCUSSION
Our results clearly show that PYRZ is highly cytotoxic to OVCAR-3 cells. Cell-killing kinetics gave sigmoidal dose-response profiles, in contrast to those of temozolomide which, as we recently reported (Jean-Claude et al, 1996) , showed a set of saturation curves. Thus, although PYRZ possesses the same structural elements as temozolomide (a 3-methyl-ureidotriazene portion), our data suggest that it is not behaving as a typical ureidotriazene-containing molecule. As shown in Figure 6 , it exhibited much weaker interactions with a 32P-labelled DNA strand in vitro than did temozolomide at a supralethal concentration (1 mM). Surprisingly, despite inducing background levels of DNA alkylation, PYRZ was capable of causing significant DNA damage in OVCAR-3 cells at 10-20 times lower concentrations. This suggests that, in contrast to temozolomide, mechanisms other than direct DNA alkylation may contribute to the cytotoxicity of PYRZ.
PYRZ induced an unusual pattern of dose-response profiles for inhibition of macromolecule synthesis in OVCAR-3 cells. In contrast to mitozolomide, temozolomide, or BCNU (Horgan et al, 1984; Jean-Claude et al, 1996) , which are known to selectively inhibit DNA synthesis, PYRZ showed a near-sigmoidal dose- due to precursor transport, as we found that the rate of thymidine transport at 3 h after treatment was unaltered. At 24 h after treatment, no inhibition of macromolecule synthesis was apparent even at concentrations corresponding to 90% cell kill (50-100 gM). An increasing trend was apparent for RNA and protein synthesis. These effects were probably caused by the activation of several repair mechanisms that involved macromolecule synthesis. Base excision and long patch repairs of DNA, induction of transcription and de novo protein synthesis may be the cause of the apparent release of the inhibition of precursor incorporation. Moreover, the inhibition of macromolecule synthesis may have little implication in the mechanism of cell killing, as it occurred only at supratoxic concentrations.
The persistent DNA lesions induced by PYRZ were consistent with a progressive increase in cell cycle accumulation in late S and G2+M in the 25-200 gM range. The block was reversed only at the lowest concentration (12.5 gM) 24 h after treatment. Cell cycle arrest in late S and G2+M may be related to a delay in DNA repair processes (Hawn et al, 1995) . This may cause the cells to miss essential transcripts required to progress through to the cycle and to die. At the concentrations that induced persistent cell cycle arrest and DNA damage, massive cell death was observed by both flow cytometric analysis and cell-killing kinetics.
Moreover, studies performed in our laboratory showed that temozolomide (1) an N-7-and 06-guanine alkylator (Catapano et al, 1987; Deans et al, 1992; Baer et al, 1993) , induced delayed cell death and cell cycle arrest in OVCAR-3 cells. Other studies by Catapano et al (1987) showed that alkali-labile sites in L1210 cells treated with temozolomide (1) were repaired within about 24 h. This type of damage was therefore excluded as the lethal injury induced by temozolomide. It should also be noted here that temozolomide-treated OVCAR-3 cells arrested in late S and G2+M, but were capable of escaping the block to later arrest in middle S, the next round of the cycle (Jean-Claude et al, 1996; Catapano et al, 1987) . Cell death induced by temozolomide may be a delayed process highly related to point mutations induced by the 06-alkylguanine adduct. In contrast, PYRZ cytotoxic activity was rapid with maximal cell killing induced within one cell cycle time and, more importantly, cell cycle arrest induced by PYRZ was mostly irreversible and eventually led to cell death.
This study conclusively demonstrated that the novel heterocycle PYRZ, despite its structural similarities to temozolomide, may have a novel and different mechanism of cell killing.
